Aerpio Overview

  • Founded
  • 2011
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 5
Employees
  • Latest Deal Type
  • M&A

Aerpio General Information

Description

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.

Contact Information

Website
www.aerpio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • 9987 Carver Road
  • Suite 420
  • Cincinnati, OH 45242
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aerpio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 26-Aug-2021 00000 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Open Market 00000 Completed Generating Revenue
7. Secondary Transaction - Open Market 00000 Completed Generating Revenue
6. PIPE 16-Mar-2017 0000 00000 Completed Generating Revenue
5. Reverse Merger 15-Mar-2017 0000 Completed Generating Revenue
4. Later Stage VC 10-Nov-2016 00.000 0000 Completed Generating Revenue
3. Later Stage VC (Series A2) 23-Apr-2014 0000 0000 000.00 Completed Generating Revenue
2. Later Stage VC (Series A1) 06-Nov-2013 $36M $41M 0000 Completed Generating Revenue
1. Later Stage VC (Series A) 05-Jan-2012 $5M $5M 00.000 Completed Startup
To view Aerpio’s complete valuation and funding history, request access »

Aerpio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A1 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 3,094,774 $0.000010 6% $1.83 $1.83 1x $1.83 7.84%
To view Aerpio’s complete cap table history, request access »

Aerpio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular dise
Drug Discovery
Cincinnati, OH
5 As of 2021
00000
000000&0 00000

000 0000

e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000000000000
Ann Arbor, MI
00 As of 0000
000.00
00000000000 000.00

00000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000 000000000
London, United Kingdom
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aerpio Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed London, United Kingdom 000 00000 000000&0 00000
000000000 Venture Capital-Backed Paris, France 00 0000 00000000000 0000
00000 000000000000 Formerly VC-backed Plano, TX 000 00.000 000000000 00.000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
You’re viewing 5 of 15 competitors. Get the full list »

Aerpio Patents

Aerpio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-6395791-B2 Antibody binding to human protein tyrosine phosphatase β (hptpβ) and use thereof Active 07-Apr-2006 000000000
ES-2643469-T3 Antibodies that bind to the human tyrosine phosphatase beta protein (hptp-beta) and uses thereof Active 07-Apr-2006 000000000
JP-2009533337-A Antibody binding to human protein tyrosine phosphatase β (hptpβ) and use thereof Granted 07-Apr-2006 000000000 0
JP-5166398-B2 Antibody binding to human protein tyrosine phosphatase β (hptpβ) and use thereof Expired - Fee Related 07-Apr-2006 000000000
JP-2019048896-A Antibodies that bind to human protein tyrosine phosphatase β(hptpβ) and uses thereof Pending 07-Apr-2006 C07K16/18
To view Aerpio’s complete patent history, request access »

Aerpio Board Members (19)

Name Representing Role Since
Chau Khuong Self Board Member 000 0000
Muneer Satter JD Self Chairman & Board Member 000 0000
You’re viewing 2 of 19 board members. Get the full list »

Aerpio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aerpio Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aerpio Therapeutics LLC Corporation Minority 000 0000 000000 0
Ally Bridge Group PE/Buyout Minority 000 0000 000000 0
Athenian Venture Partners Venture Capital Minority 000 0000 000000 0
CincyTech Venture Capital Minority 000 0000 000000 0
GeneChem Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Aerpio Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 27-Aug-2021 0000000 00 Drug Discovery
To view Aerpio’s complete acquisitions history, request access »